Edition:
United Kingdom

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

682.85INR
10:27am GMT
Change (% chg)

Rs-5.90 (-0.86%)
Prev Close
Rs688.75
Open
Rs692.50
Day's High
Rs699.00
Day's Low
Rs675.00
Volume
157,079
Avg. Vol
326,092
52-wk High
Rs878.00
52-wk Low
Rs555.00

Chart for

About

Jubilant Life Sciences Limited is an India-based pharmaceutical and life sciences company. The Company is engaged in providing basic organic chemicals. The Company's segments include Pharmaceuticals and Life Sciences Ingredients. The Pharmaceuticals segment consists of generics, including active pharmaceuticals ingredients... (more)

Overall

Beta: 1.54
Market Cap(Mil.): Rs105,929.90
Shares Outstanding(Mil.): 159.28
Dividend: 3.00
Yield (%): 0.45

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Jubilant Life Sciences Says Co Not Got Formal Environmental Nod For Gujarat Pesticide Project

* CLARIFIES ON NEWS ITEM ON CO'S PESTICIDE PROJECT IN GUJARAT GETTING GREEN PANEL NOD

04 Dec 2017

BRIEF-Jubilant Life Sciences' unit to buy entire equity share capital of Jubilant Discovery Services ​

* Unit ‍drug Discovery and Development Solutions to buy entire equity share capital of Jubilant Discovery Services Inc​

22 Nov 2017

BRIEF-Jubilant Life Sciences issues commercial papers worth 500 mln rupees ‍​

Nov 3 Jubilant Life Sciences Ltd * Issued commercial papers worth 500 million rupees ‍​ Source text - http://bit.ly/2iZFtyJ Further company coverage:

03 Nov 2017

BRIEF-Jubilant Life Sciences issues commercial papers worth 500 mln rupees‍​

* Issues commercial papers worth 500 million rupees‍​ Source text: (http://bit.ly/2zui6kx) Further company coverage:

17 Oct 2017

BRIEF-India's Jubilant Life Sciences June-qtr consol profit down about 12 pct

* June quarter consol net profit 1.44 billion rupees versus profit of 1.64 billion rupees last year

18 Jul 2017

BRIEF-Jubilant Life Sciences gets ANDA nod for generic drug to treat depression

* Says Jubilant receives ANDA approval for bupropion hydrochloride extended-release tablets

06 Jul 2017

Earnings vs. Estimates